Biotech companies race to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.
Average biomedical Ph.D. takes five to six years to complete, but DHS wants to limit visas to four years. Experts warn of harm to U.S. research.
An advisory committee is set to review the treatment, called RP1, that has been at the center of heated debate over agency standards.
Fauci to face questions on Covid origin as Health Secretary Robert F. Kennedy Jr. and Sen. Rand Paul, R-Ky., have discussed Fauci's prosecution.
New CEO Luke Miels used the company's earnings report to outline a strategy that he said could put the company on a path to long-term growth.
ProMIS Neurosciences is developing a drug to try to clear amyloid from the brain with lower side effect rates than approved medicines have.
Growing awareness of the painful condition is good news for women of color, who have double the prevalence of PMOS and often go undiagnosed.
Breakthroughs in dementia care are creating a new economy of tests, drugs and risk calculators.
The Centers for Medicaid and Medicare Services' Health Tech Ecosystem seeks to advance data interoperability without federal regulations.
Play: What's the word? Test your knowledge with today's mini crossword
